Vernalis Ltd., Granta Park, Great Abington, Cambridge, UK.
Bioorg Med Chem. 2012 Nov 15;20(22):6770-89. doi: 10.1016/j.bmc.2012.08.050. Epub 2012 Sep 4.
Inhibitors of the Hsp90 molecular chaperone are showing promise as anti-cancer agents. Here we describe a series of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors that were identified following structure-driven optimization of purine hits revealed by NMR based screening of a proprietary fragment library. Ligand-Hsp90 X-ray structures combined with molecular modeling led to the rational displacement of a conserved water molecule leading to enhanced affinity for Hsp90 as measured by fluorescence polarization, isothermal titration calorimetry and surface plasmon resonance assays. This displacement was achieved with a nitrile group, presenting an example of efficient gain in binding affinity with minimal increase in molecular weight. Some compounds in this chemical series inhibit the proliferation of human cancer cell lines in vitro and cause depletion of oncogenic Hsp90 client proteins and concomitant elevation of the co-chaperone Hsp70. In addition, one compound was demonstrated to be orally bioavailable in the mouse. This work demonstrates the power of structure-based design for the rapid evolution of potent Hsp90 inhibitors and the importance of considering conserved water molecules in drug design.
Hsp90 分子伴侣抑制剂作为抗癌药物具有广阔的应用前景。在此,我们描述了一系列基于结构的嘌呤类苗头化合物的优化,通过基于 NMR 的专利片段文库筛选发现了 4-芳基-5-氰基吡咯并[2,3-d]嘧啶 ATP 竞争性 Hsp90 抑制剂。配体-Hsp90 X 射线结构结合分子建模,导致保守水分子的合理置换,从而导致通过荧光偏振、等温滴定量热法和表面等离子体共振测定法测量的 Hsp90 亲和力增强。这种取代是通过氰基基团实现的,为我们提供了一个通过最小程度增加分子量来有效提高结合亲和力的范例。该化学系列中的一些化合物可在体外抑制人类癌细胞系的增殖,并导致致癌 Hsp90 客户蛋白的耗竭以及共伴侣 Hsp70 的同时升高。此外,已经证明一种化合物在小鼠中具有口服生物利用度。这项工作证明了基于结构的设计在快速进化出强效 Hsp90 抑制剂方面的强大作用,以及在药物设计中考虑保守水分子的重要性。